These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
46 related articles for article (PubMed ID: 38653622)
1. No clinical benefit from sequential combination of mitomycin C plus bacillus Calmette-Guérin (BCG) than BCG alone in the adjuvant treatment of high risk non muscle invasive bladder cancer: result of a planned interim analysis of a prospective randomized trial. Cicione A; Lombardo R; Nacchia A; Franco A; Simone G; Pastore A; Leonardo C; Franco G; Tubaro A; DE Nunzio C Minerva Urol Nephrol; 2024 Jun; ():. PubMed ID: 38842053 [TBL] [Abstract][Full Text] [Related]
2. N-803 Plus BCG Treatment for BCG-Naïve or -Unresponsive Non-Muscle Invasive Bladder Cancer: A Plain Language Review. Chamie K; Chang SS; Rosser CJ; Kramolowski E; Gonzalgo ML; Sexton WJ; Spilman P; Sender L; Reddy S; Soon-Shiong P Future Oncol; 2024 Jul; ():1-11. PubMed ID: 38953850 [TBL] [Abstract][Full Text] [Related]
6. A Multinational, Multi-Institutional Study Assessing the Impact of Diabetes Mellitus on the Prognosis of Patients with Non-Muscle Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin. Abou Chakra M; Duquesne I; Peyromaure M; Mott SL; Moussa M; O'Donnell MA Nutr Cancer; 2024 Jul; ():1-9. PubMed ID: 38973234 [TBL] [Abstract][Full Text] [Related]
7. Use of Bladder-Related Medication in Non-Muscle Invasive Bladder Cancer Patients. Blichert-Refsgaard L; Graugaard-Jensen C; Nørgaard M; Jensen JB Cancers (Basel); 2024 May; 16(10):. PubMed ID: 38792014 [TBL] [Abstract][Full Text] [Related]
8. Comparative analysis of adverse events among intravesical drugs in bladder cancer: a real-world study on FAERS database. Peng Y; Song Y; Du Y; Qin C; Xu T Expert Opin Drug Saf; 2024 Jul; ():1-8. PubMed ID: 38946478 [TBL] [Abstract][Full Text] [Related]
9. Atypical B cells promote cancer progression and poor response to Bacillus Calmette-Guérin in non-muscle invasive bladder cancer. Yolmo P; Rahimi S; Chenard S; Conseil G; Jenkins D; Sachdeva K; Emon I; Hamilton J; Xu M; Rangachari M; Michaud E; Mansure JJ; Kassouf W; Berman DM; Siemens DR; Koti M Cancer Immunol Res; 2024 Jun; ():. PubMed ID: 38916567 [TBL] [Abstract][Full Text] [Related]
10. Use of atezolizumab in bacillus Calmette-Guérin-unresponsive high-risk non-muscle-invasive bladder cancer. Akinsola OA; Talwar R; Baskin A; Luckenbaugh AN; Al Hussein Al Awamlh B Transl Androl Urol; 2024 Jun; 13(6):1061-1063. PubMed ID: 38983471 [No Abstract] [Full Text] [Related]
11. Selecting the right treatment: Health outcome priorities in older patients with bladder cancer. Rutten VC; Al CM; Festen S; Zuiverloon TCM; Boormans JL; Polinder-Bos HA J Geriatr Oncol; 2024 Jul; 15(6):101811. PubMed ID: 38896950 [TBL] [Abstract][Full Text] [Related]
12. Quality of Life in Patients with High-grade Non-muscle-invasive Bladder Cancer Undergoing Standard Versus Reduced Frequency of Bacillus Calmette-Guérin Instillations: The EAU-RF NIMBUS Trial. van Straten CGJI; Caris C; Grimm MO; Colombel M; Muilwijk T; Martínez-Piñeiro L; Babjuk MM; Türkeri LN; Palou J; Patel A; Bjartell AS; Witjes WPJ; van der Heijden AG; Kiemeney LALM Eur Urol Open Sci; 2023 Oct; 56():15-24. PubMed ID: 37822514 [TBL] [Abstract][Full Text] [Related]
13. Effects of acupuncture to decrease adverse events in patients with high-risk non-muscle invasive bladder cancer receiving induction intravesical BCG therapy: Study protocol for a randomized, controlled pilot and feasibility study. Psutka SP; Veleber S; Siman J; Jannat S; Holt S; Wright JL; Greenlee H Contemp Clin Trials Commun; 2022 Dec; 30():101044. PubMed ID: 36561732 [TBL] [Abstract][Full Text] [Related]